[go: up one dir, main page]

MA31953B1 - Nouveaux derives du thiophene. - Google Patents

Nouveaux derives du thiophene.

Info

Publication number
MA31953B1
MA31953B1 MA32972A MA32972A MA31953B1 MA 31953 B1 MA31953 B1 MA 31953B1 MA 32972 A MA32972 A MA 32972A MA 32972 A MA32972 A MA 32972A MA 31953 B1 MA31953 B1 MA 31953B1
Authority
MA
Morocco
Prior art keywords
thiophene
new derivatives
preparation
derivatives
compounds
Prior art date
Application number
MA32972A
Other languages
Arabic (ar)
English (en)
Inventor
Martin Bolli
Cyrille Lescop
Boris Mathys
Claus Mueller
Oliver Nayler
Beat Steiner
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31953B1 publication Critical patent/MA31953B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés du thiophène, leur préparation et leur utilisation en tant que composés pharmaceutiquement actifs. Lesdits composés agissent notamment comme agents immunomodulateurs.
MA32972A 2007-12-10 2010-06-30 Nouveaux derives du thiophene. MA31953B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007054991 2007-12-10
PCT/IB2008/055156 WO2009074950A2 (fr) 2007-12-10 2008-12-09 Nouveaux dérivés du thiophène

Publications (1)

Publication Number Publication Date
MA31953B1 true MA31953B1 (fr) 2010-12-01

Family

ID=40640372

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32972A MA31953B1 (fr) 2007-12-10 2010-06-30 Nouveaux derives du thiophene.

Country Status (15)

Country Link
US (1) US8148410B2 (fr)
EP (1) EP2222667B1 (fr)
JP (1) JP5503551B2 (fr)
KR (1) KR20100095593A (fr)
CN (1) CN101896482B (fr)
AU (1) AU2008334297A1 (fr)
BR (1) BRPI0820868A2 (fr)
CA (1) CA2706834A1 (fr)
ES (1) ES2403209T3 (fr)
IL (1) IL206221A0 (fr)
MA (1) MA31953B1 (fr)
MX (1) MX2010005889A (fr)
RU (1) RU2010128006A (fr)
TW (1) TW200930363A (fr)
WO (1) WO2009074950A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
MY149853A (en) * 2006-09-07 2013-10-31 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
TWI408139B (zh) * 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
CL2007002594A1 (es) * 2006-09-08 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
DK2125797T3 (da) * 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
WO2009109906A1 (fr) * 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Composés de pyridine
SI2252609T1 (sl) * 2008-03-07 2013-07-31 Actelion Pharmaceuticals Ltd. Derivati piridin-2-ila kot imunomodulacijska sredstva
EP2262782B1 (fr) * 2008-03-07 2012-07-04 Actelion Pharmaceuticals Ltd. Nouveaux dérivés d'aminométhylbenzène
CA2767585C (fr) 2009-07-16 2017-09-26 Actelion Pharmaceuticals Ltd Derives pyridin-4-yliques
EP2560969B1 (fr) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company Amides du 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-acide mandelique comme agonistes du sphingosin-1-phosphate 1 recepteur
ES2548258T3 (es) 2010-09-24 2015-10-15 Bristol-Myers Squibb Company Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
MX350009B (es) 2011-01-19 2017-08-23 Idorsia Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo.
US9000016B2 (en) * 2012-11-05 2015-04-07 Allergan, Inc. 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators
KR102220848B1 (ko) 2015-05-20 2021-02-26 이도르시아 파마슈티컬스 리미티드 화합물 (s)-3-｛4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시｝-프로판-1,2-디올의 결정형
EP3371177A1 (fr) 2015-11-02 2018-09-12 Basf Se Utilisation d'oxadiazoles substitués pour lutter contre les champignons phytopathogènes
EP3165094A1 (fr) 2015-11-03 2017-05-10 Basf Se Oxadiazoles substitués pour lutter contre les champignons phytopathogènes
EP3370525A1 (fr) 2015-11-04 2018-09-12 Basf Se Utilisation d'oxadiazoles substitués pour lutter contre les champignons phytopathogènes
BR112018009579A2 (pt) 2015-11-13 2018-11-06 Basf Se composto da fórmula i, mistura, composição agroquímica, uso de composto e método de combate a fungos
US20180354920A1 (en) 2015-11-13 2018-12-13 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10674727B2 (en) 2015-11-19 2020-06-09 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
JP2019502661A (ja) 2015-11-19 2019-01-31 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 植物病原菌を駆除するための置換オキサジアゾール
EP3442951A1 (fr) 2016-04-11 2019-02-20 Basf Se Oxadiazoles substitués pour lutter contre des champignons phytopathogènes
BR112018074569B1 (pt) 2016-06-09 2022-10-04 Basf Se Compostos, uso de n-(2,4-difluorofenil)-4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il] benzamida, composição agroquímica e método para combater fungos nocivos fitopatogênicos
WO2017211650A1 (fr) 2016-06-09 2017-12-14 Basf Se Oxadiazoles substitués pour lutter contre des champignons phytopathogènes
US20190322631A1 (en) 2016-12-19 2019-10-24 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3339297A1 (fr) 2016-12-20 2018-06-27 Basf Se Oxadiazoles substitués pour lutter contre les champignons phytopathogènes
WO2018153730A1 (fr) 2017-02-21 2018-08-30 Basf Se Oxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
EP3606912A1 (fr) 2017-04-07 2020-02-12 Basf Se Oxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
WO2018188962A1 (fr) 2017-04-11 2018-10-18 Basf Se Oxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
WO2018202491A1 (fr) 2017-05-04 2018-11-08 Basf Se Trifluorométhyloxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
WO2018219797A1 (fr) 2017-06-02 2018-12-06 Basf Se Oxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
US20200190043A1 (en) 2017-06-19 2020-06-18 Basf Se 2-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]aryloxy](thio)acetamides for combating phytopathogenic fungi
WO2019002158A1 (fr) 2017-06-30 2019-01-03 Basf Se Trifluorométhyloxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
WO2019025250A1 (fr) 2017-08-04 2019-02-07 Basf Se Trifluorométhyloxadiazoles substitués permettant de lutter contre des champignons phytopathogènes
WO2019038042A1 (fr) 2017-08-21 2019-02-28 Basf Se Trifluorométhyloxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
US11076596B2 (en) 2017-09-18 2021-08-03 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
EP3713936B1 (fr) 2017-11-23 2021-10-20 Basf Se Trifluorométhyl-oxadiazoles substitués pour lutter contre les champignons phytopathogènes
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
WO2025201332A1 (fr) * 2024-03-26 2025-10-02 勤浩医药（苏州）有限公司 Composé oxadiazole, composition pharmaceutique le comprenant et leur utilisation
CN120309605B (zh) * 2025-06-12 2025-09-02 长江大学 一种苯并噁嗪-Tioxazafen衍生物及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1092929B (de) 1959-04-16 1960-11-17 Hoechst Ag Verfahren zur Herstellung von substituierten Thiophen-2-carbonsaeureestern bzw. den freien Carbonsaeuren
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
CN1223648A (zh) * 1996-07-01 1999-07-21 山之内制药株式会社 新颖的噻吩衍生物及其医药组合物
TW414795B (en) 1996-07-01 2000-12-11 Yamanouchi Pharma Co Ltd A thiophene derivative and the pharmaceutical composition
EP1070080A4 (fr) 1998-03-09 2004-12-29 Smithkline Beecham Corp POLYNUCLEOTIDES ET POLYPEPTIDES D'EDG-1c HUMAIN ET LEURS PROCEDES D'UTILISATION
WO2000063194A1 (fr) * 1999-04-19 2000-10-26 Shionogi & Co., Ltd. Derives de sulfonamide possedant des noyaux oxadiazole
WO2001083464A1 (fr) * 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire
CN1199956C (zh) * 2000-04-21 2005-05-04 盐野义制药株式会社 具有抗癌作用的噁二唑衍生物
WO2003062252A1 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Agonistes du recepteur edg
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
WO2004035538A1 (fr) 2002-10-15 2004-04-29 Merck & Co., Inc. Procede de fabrication de l'acide azetidine-3-carboxylique
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
CA2547198A1 (fr) 2003-12-17 2005-06-30 Merck & Co., Inc. Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
WO2006010379A1 (fr) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Nouveaux derives du thiophene utilises comme agents immunosupresseurs
WO2006047195A2 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
US7846964B2 (en) 2005-03-23 2010-12-07 Actelion Pharmaceuticals Ltd. Thiophene derivatives as spingosine-1-phosphate-1 receptor agonists
CN101146529B (zh) 2005-03-23 2012-08-29 埃科特莱茵药品有限公司 新颖噻吩衍生物作为鞘氨醇-1-磷酸酯-1受体激动剂
EP1863787B1 (fr) 2005-03-23 2011-05-25 Actelion Pharmaceuticals Ltd. Derives hydrogenes de benzo (c) thiophene utilises comme immunomodulateurs
KR20070121013A (ko) 2005-04-22 2007-12-26 다이이찌 산쿄 가부시키가이샤 헤테로 고리 화합물
AU2006239418A1 (en) 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
EP1893591A1 (fr) 2005-06-08 2008-03-05 Novartis AG Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p
CA2612661A1 (fr) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Nouveaux derives de thiofene
US20090054491A1 (en) 2005-06-28 2009-02-26 Astrazeneca Ab Use
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
JP5063615B2 (ja) 2006-01-24 2012-10-31 アクテリオン ファーマシューティカルズ リミテッド 新規ピリジン誘導体
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
JP2008120794A (ja) * 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
EP2109364A4 (fr) 2006-12-15 2010-04-14 Abbott Lab Composés d'oxadiazole innovants
WO2008091967A1 (fr) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Composés chimiques
DK2291080T3 (en) 2008-05-14 2015-12-07 Scripps Research Inst Novel modulator of sphingosinphosphatreceptorer

Also Published As

Publication number Publication date
BRPI0820868A2 (pt) 2019-09-24
WO2009074950A3 (fr) 2009-08-06
CN101896482A (zh) 2010-11-24
US20100261702A1 (en) 2010-10-14
JP5503551B2 (ja) 2014-05-28
AU2008334297A1 (en) 2009-06-18
WO2009074950A2 (fr) 2009-06-18
EP2222667A2 (fr) 2010-09-01
RU2010128006A (ru) 2012-01-20
IL206221A0 (en) 2010-12-30
KR20100095593A (ko) 2010-08-31
ES2403209T3 (es) 2013-05-16
CA2706834A1 (fr) 2009-06-18
JP2011506423A (ja) 2011-03-03
EP2222667B1 (fr) 2013-02-20
CN101896482B (zh) 2013-01-09
MX2010005889A (es) 2010-06-22
TW200930363A (en) 2009-07-16
US8148410B2 (en) 2012-04-03

Similar Documents

Publication Publication Date Title
MA31953B1 (fr) Nouveaux derives du thiophene.
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
MA30765B1 (fr) Derives innovants du thiophene
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
WO2006100635A3 (fr) Nouveaux derives de thiophene
EA201170703A1 (ru) Производные адамантилбензамида
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
MY147949A (en) Hydrogenated benzo[c]thiophene derivatives as immunomodulators
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
NO20083630L (no) Nye pyridinderivater
MA38432A1 (fr) Nouveaux dérivés d'octahydro-pyrrolo [3,4-c]-pyrrole et analogues de ceux-ci servant d'inhibiteurs d'autotaxine
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA31703B1 (fr) Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
EA200901319A1 (ru) Композиции для назального введения
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA33528B1 (fr) Derives pyridin-4-yliques
MA31988B1 (fr) Derives d'aminopyrazole
TW200942524A (en) Novel aminomethyl benzene derivatives